RENAL FUNCTION IN TRANSFUSION-DEPENDENT Β-THALASSEMIA PATIENTS: A DECADE OF FOLLOW-UP AND COMPARISON BETWEEN CHELATION REGIMES

EHA Library, Carina Levin, 215523

GENETIC STUDIES REVEAL NEW MUTATIONS IN THE CP GENE IN ACERULOPLASMINEMIA PATIENTS

EHA Library, Giacomo Marchi, 215524

DIAGNOSIS OF HEREDITARY HAEMATOLOGICAL DISEASES USING NEXT GENERATION SEQUENCING PANELS

EHA Library, Mayka Sanchez Fernandez, 215525

HEMATOPOIETIC IMPROVEMENT AFTER DEFERASIROX TREATMENT IN A CHILD WITH APLASTIC ANEMIA

EHA Library, Gizem Ersoy, 215526

TREATMENT WITH FERRIC CARBOXYMALTOSE FOR SEVERE IRON DEFICIENCY ANEMIA IN STABLE NOT ACTIVELY BLEEDING PATIENTS IN THE EMERGENCY DEPARTMENT

EHA Library, Irene Motta, 215527

IRON DEFICIENCY ANAEMIA – ZINC PROTOPORPHYRIN, A SIMPLE, FAST, INEXPENSIVE DIAGNOSTIC METHOD

EHA Library, João Gomes, 215528

STUDY OF A MEDICO-ECONOMIC ADVANTAGE IN USING NEW PARAMETERS OF CBC-DIFF-RETIC IN THE EARLY DETECTION OF IRON DEFICIENCY FOR DIALYSIS PATIENTS**

EHA Library, Elena Sukhacheva, 215529

ACERULOPLASMINAEMIA - THE EXTREMELY RARE ALSO EXISTS

EHA Library, João Gomes, 215530

IT TAKES A LOT OF IRON TO AVOID TRANSFUSION

EHA Library, Magda Jabbar Al-Obaidi, 215531

PANCREATIC IRON LOADING IN EMOGLOBINOPATHIES.

EHA Library, Alessia Pepe, 215532

CHR AND %HYPO: BETTER METHODS FOR ASSESSING FUNCTIONAL IRON DEFICIENCY IN CHRONIC KIDNEY DISEASE?

EHA Library, Laura Smith, 215533

GROWING IMPORTANCE OF FLOW CYTOMETRY (FCM) IN THE DIAGNOSTICS OF MYELODYSPLASTIC SYNDROMES: SENSITIVITY AND SPECIFICITY OF THE UP-TO-DATE SCORING SYSTEMS UNDER SPECIAL CONSIDERATION OF THE NEW IFSCORE

EHA Library, Uta OELSCHLAEGEL, 215534

EXPLORING THE LONG NON-CODING RNA TRANSCRIPTOME IN JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Mattias Hofmans, 215535

A MIR-150 / TET3 PATHWAY REGULATES THE GENERATION OF MOUSE AND HUMAN NON-CLASSICAL MONOCYTE SUBSET

EHA Library, Dorothée Selimoglu-Buet, 215536

IMPACT OF RED BLOOD CELL TRANSFUSION RATE, ADJUSTED BY THERAPEUTIC INTERVENTIONS, ON PROGRESSION-FREE SURVIVAL IN LOWER RISK MDS PATIENTS WITHIN THE EUROPEAN LEUKEMIANET MDS REGISTRY

EHA Library, Louise de Swart, 215537

EXPRESSION PATTERN OF LONG-NONCODING RNAS ALTERS IN DIFFERENT FORMS OF MYELODYSPLASTIC SYNDROMES

EHA Library, Katarina Szikszai, 215538

MDS WITH P53 DYSFUNCTION: A NEW PROGNOSTIC AND PREDICTIVE CATEGORY. A STUDY FROM THE ITALIAN MDS CLINICAL NETWORK

EHA Library, Marianna rossi, 215539

A FLOW-CYTOMETRY SCORING SYSTEM OF ABNORMAL GRANULOCYTES AND MONOCYTES MATURATION PROFILES FOR DIAGNOSIS OF MYELODYSPLASTIC SYNDROMES

EHA Library, Nicolas Chapuis, 215540

ALTERED CARBONYLATION PATTERN IN MYELODISPLASTIC SYNDROMES

EHA Library, Alba Rodríguez-García, 215541

EXPRESSION LEVEL OF SPECIFIC MIRNAS BEFORE AZACITIDINE THERAPY INITIATION MAY PREDICT FUTURE EFFICACY OF THE TREATMENT IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA

EHA Library, Michaela Dostalova Merkerova, 215542

MULTICENTRIC VALIDATION OF THE “MONOCYTE ASSAY” FOR CHRONIC MYELOMONOCYTIC LEUKEMIA DIAGNOSIS BY FLOW CYTOMETRY

EHA Library, Orianne Wagner-Ballon, 215543

CHARACTERIZATION AND DIFFERENTIAL EFFECTS OF MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Manja Wobus, 215544

MYELODISPLASTIC SYNDROMES: MECHANISMS INVOLVED IN THE TRANSFORMATION TO ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Francisca Hernández Mohedo, 215545

COMPLETE BLOOD COUNT- BASED SCORE FOR THE DIAGNOSIS AND PROGNOSIS OF MYELODYSPLASTIC SYNDROMES IN CYTOPENIC PATIENTS

EHA Library, Marion Eveillard, 215546

AUTOPHAGY IN MYELODYSPLASTIC SYNDROMES: THE ROLE OF HIF-1A/REDD1 MOLECULAR PATHWAY

EHA Library, IOANNA STERGIOU, 215547

AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DURVALUMAB IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AFTER TREATMENT WITH HYPOMETHYLATING AGENTS

EHA Library, Guillermo Garcia-Manero, 215548

SINGLE AGENT TALACOTUZUMAB IN ELDERLY HIGH-RISK MDS OR AML PATIENTS FAILING HYPOMETHYLATING AGENTS – RESULTS OF THE SAMBA STUDY BY THE EMSCO NETWORK

EHA Library, Uwe Platzbecker, 215549

HYPOMETHYLATING AGENTS ASSOCIATED INFECTIONS - SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

EHA Library, Liat Shargian, 215550

RESPONSE TO HYPOMETHYLATING AGENTS IMPROVES LONG-TERM OUTCOMES FOR LOWER-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROME IN CASE-MATCHED COHORTS

EHA Library, Dongwon Baek, 215551

A SYSTEMATIC REVIEW PROVIDES LIMITED CLINICAL EVIDENCE FOR ADDITIONAL EFFICACY OF G-CSF + ESA COMPARED TO FULL-DOSE ESA ALONE IN THE TREATMENT OF ANEMIA IN PATIENTS WITH LOW-RISK MDS

EHA Library, Lucas Affentranger, 215552

LOW RISK MDS WITHOUT RING SIDEROBLASTS. CLINICAL AND BIOLOGICAL CHARACTERIZATION FROM THE SPANISH GROUP OF MDS.

EHA Library, Felix Lopez Cadenas, 215553

SEROTONIN RECEPTOR TYPE 1B CONSTITUTES A THERAPEUTIC TARGET FOR MDS AND CMML.

EHA Library, Antònia BANÚS MULET, 215554

INTENSIVE CHEMOTHERAPY (IC) IS MORE EFFECTIVE THAN HYPOMETHYLATING AGENTS (HMA) FOR THE TREATMENT OF YOUNGER PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ELEVATED BONE MARROW BLASTS

EHA Library, Paolo Strati, 215555

FETAL HEMOGLOBIN INDUCTION DURING DECITABINE TREATMENT OF ELDERLY MDS/AML PATIENTS: A POTENTIAL DYNAMIC BIOMARKER FOR OUTCOME

EHA Library, Julia Stomper, 215556

CLINICAL IMPACT ON THE THERAPEUTIC STRATEGY ADAPTED TO THE MUTATIONAL PROFILE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH DEL(5Q)

EHA Library, Carolina Alarcón-Payer, 215557

CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH 5-AZACYTIDINE. RESULTS FROM THE HELLENIC 5-AZACYTIDINE REGISTRY.

EHA Library, Panagiotis Diamantopoulos, 215558

OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND STABLE DISEASE DURING TREATMENT WITH AZACITIDINE: A REPORT FROM GRUPPO ROMANO MIELODISPLASIE (GROM) AND RETE EMATOLOGICA LOMBARDA (REL).

EHA Library, Luca Maurillo, 215559

PREDICTIVE FACTORS OF OVERALL SURVIVAL AND TREATMENT RESPONSE IN HIGH-RISK OLDER PATIENTS WITH MDS AND CMML UNDER HYPOMETHILATING AGENTS. LATIN-AMERICAN MDS GROUP - GLAM

EHA Library, Marcelo Iastrebner, 215560

IRON SUPPORT ENHANCES ERYTHROPOIETIN EFFECTIVENESS IN REFRACTORY ANEMIA WITH HIGH RETICULOCYTE COUNT, TRANSFERRIN SATURATION BELOW 30% AND HIGH LEVEL OF ERYPTOSIS.

EHA Library, GIULIO GIORDANO, 215561

SEVERE THROMBOCYTOPENIA AS A PREDICTOR OF SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS: DATA FROM A LATIN-AMERICAN COHORT

EHA Library, Carolina Lazzarino, 215563

TLR4 SIGNALING DRIVES MESENCHYMAL STEM CELLS (MSC) COMMITMENT TO PROMOTE TUMOR MICROENVIRONMENT TRANSFORMATION IN MULTIPLE MYELOMA

EHA Library, Cesarina Giallongo, 215564

BI-ALLELIC LOSS OF FAM46C BY CRISPR/CAS9 SYSTEM ENHANCES MYELOMA CELL GROWTH

EHA Library, KANASUGI JO, 215565

MOLECULAR SEGMENTATION OF MULTIPLE MYELOMA BY INTEGRATIVE MULTI-OMICS ANALYSIS

EHA Library, Maria Ortiz Estevez, 215566

SYSTEMATIC IDENTIFICATION OF PHARMACOGENOMICS INTERACTIONS MODULATING DRUG RESPONSES IN MULTIPLE MYELOMA

EHA Library, Muntasir Majumder, 215567

ADAR1-MEDIATED-NEIL1 EDITING IS OF BIOLOGICAL SIGNIFICANCE IN MULTIPLE MYELOMA

EHA Library, Phaik Ju Teoh, 215568

IRON INCREASES THE EFFICACY OF STANDARD MULTIPLE MYELOMA THERAPY IN TRANSGENIC VK*MYC MODEL

EHA Library, Jessica Bordini, 215569

BONE MARROW MACROPHAGES IN PATIENTS WITH MULTIPLE MYELOMA IN COMPLETE REMISSION RETAIN PRO-TUMOR M2 PHENOTYPE

EHA Library, Ester Lozano, 215570

PTC-028 DEMONSTRATES POTENT PRE-CLINICAL ACTIVITY AND PROVIDES A NOVEL OPPORTUNITY TO MODULATE BMI1 IN MULTIPLE MYELOMA

EHA Library, Heinz Ludwig, 215571

ARGININE DEPRIVATION SUSTAINS PLASMA CELL FITNESS AND BIOENERGETICS IN MULTIPLE MYELOMA

EHA Library, Alessandra Romano, 215572

DEMETHYLATION SENSITISES T(4;14) MULTIPLE MYELOMA TO RAS-MAPK PATHWAY INHIBITION

EHA Library, Jay Hocking, 215573

CD96 (TACTILE) NEGATIVELY REGULATES THE CYTOTOXIC FUNCTIONS OF NATURAL KILLER CELLS AGAINST MULTIPLE MYELOMA

EHA Library, Michael O'Dwyer, 215574

GLUTAMINE-DEPENDENCE TARGETING BY ASPARAGINASE SIGNIFICANTLY INCREASES ANTI-MM ACTIVITY OF PROTEASOME INHIBITION

EHA Library, Paola Minetto, 215575

MITOCHONDRIAL ACTIVITY PLAYS A CRITICAL ROLE IN MULTIPLE MYELOMA RESISTANCE

EHA Library, Alejandra Ortiz, 215576

ELOTUZUMAB PROMOTES SELF-ENGAGEMENT OF SLAMF7 BETWEEN NATURAL KILLER AND MULTIPLE MYELOMA CELLS TO ENHANCE CYTOTOXICITY

EHA Library, Michael D. Robbins, 215577

CARFILZOMIB-INDUCED CARDIOTOXICITY: MOLECULAR MECHANISMS AND THE EMERGING ROLE OF METFORMIN AS A PROPHYLACTIC THERAPY

EHA Library, Evangelos Terpos, 215578

JAGGED1/2 INHIBITION PROMOTES TUMOR CELLS RESPONSE TO BORTEZOMIB IN A ZEBRAFISH MODEL OF MULTIPLE MYELOMA

EHA Library, Maria Teresa Palano, 215579

TGFΒ INHIBITION IN COMBINATION WITH CHEMOTHERAPY REPAIRS EXISTING LYTIC BONE LESIONS IN A NOVEL PLATEAU PHASE MODEL OF MULTIPLE MYELOMA

EHA Library, Andrew Chantry, 215580

MULTIPLE MYELOMA: SINGLE PLARFORM ABSOLUTE COUNT OF CIRCULATING PLASMA CELLS AT DIAGNOSIS CORRELATE WITH POOR PROGNOSIS PARAMETERS.

EHA Library, Vittorio Emanuele Muccio, 215581

MULTIPLE MYELOMA PATHOGENESIS: THE ROLE OF JUNB IN BONE MARROW ANGIOGENESIS

EHA Library, Stefano Malvestiti, 215582

TARGETED LIPOSOMAL MULTI-DRUG DELIVERY TO TUMOR-ASSOCIATED ENDOTHELIUM AS A NOVEL STRATEGY TO REVERSE MICROENVIRONMENT-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA

EHA Library, Cinzia Federico, 215583

WNT/Β-CATENIN AND HEDGEHOG INHIBITORS AS THERAPEUTIC APPROACHES IN B-CELL NEOPLASMS

EHA Library, Ana Bela Sarmento Ribeiro, 215584

MULTIPLE MYELOMA INDUCES CHANGES IN BONE MARROW ADIPOCYTES IN VITRO AND IN VIVO

EHA Library, Michaela Reagan, 215585

PROTEIN KINASE CK1 ALPHA MODULATES PROSURVIVAL AUTOPHAGY IN MULTIPLE MYELOMA

EHA Library, Marilena Carrino, 215586

SERUM LIPID METABOLOMICS AS AN USEFUL BIOMARKER PREDICTING FOR THE EFFICACY OF　BORTEZOMIB TREATMENT AND PERIPHERAL NEUROPATHY IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Masaki Ri, 215587

CIRCULATING SOLUBLE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS REFLECTS RENAL FUNCTION IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TREATED WITH BORTEZOMIB-BASED THERAPY

EHA Library, Evangelos Terpos, 215588

PAN-ANTI-FGF-BASED THERAPY AS A NOVEL THERAPEUTIC INTERVENTION IN WALDENSTROM’S MACROGLOBULINEMIA

EHA Library, Antonio Sacco, 215589

EVALUATION OF THE ACTIVITY OF IMIDS IN MM PROLIFERATING CELLS

EHA Library, Joan Ballesteros, 215590

ADDITION OF VORINOSTAT TO LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MYELOMA DOES NOT IMPROVE OUTCOMES: RESULTS OF THE MYELOMA XI TRIAL

EHA Library, Matthew Jenner, 215591

POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE-BASED TREATMENT FAILURE

EHA Library, David S. Siegel, 215592

DOUBLET VS TRIPLET LENALIDOMIDE-CONTAINING REGIMENS FOLLOWED BY MAINTENANCE: SUBGROUP ANALYSIS BY FRAILTY STATUS AFTER A MEDIAN FOLLOW-UP OF 5 YEARS (EMN01 PHASE III STUDY)

EHA Library, Sara Bringhen, 215593

POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN CASE OF SUBOPTIMAL RESPONSE TO POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: RESULTS OF THE GMMG-PERSPECTIVE TRIAL

EHA Library, Katja Weisel, 215594

SKY92 RISK STRATIFICATION AT RELAPSE PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR STANDARD-RISK MULTIPLE MYELOMA PATIENTS

EHA Library, Rowan Kuiper, 215595

CARFILZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE IN TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PRELIMINARY RESULT OF SGHMM1 TRIAL, HIGH-RISK COHORT (NCT02217163)

EHA Library, Chandramouli Nagarajan, 215596

WEEKLY CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A PHASE 1B STUDY

EHA Library, Noa Biran, 215597

EXTENDED 5-Y FOLLOW-UP OF PHASE 3 ELOQUENT-2 STUDY: ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Katja Weisel, 215598

LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS.

EHA Library, Francesca Gay, 215599

A GLOBAL TREATMENT STANDARD IN MULTIPLE MYELOMA (MM) REMAINS ELUSIVE DESPITE ADVANCES IN CARE OVER 15 YEARS: FIRST RESULTS FROM INSIGHT MM, THE LARGEST GLOBAL PROSPECTIVE, OBSERVATIONAL MM STUDY

EHA Library, Mario Boccadoro, 215600

TREATMENT AND SURVIVAL OF PATIENTS WITH PRIMARY PLASMA CELL LEUKEMIA: A NATIONWIDE POPULATION-BASED STUDY AMONG 179 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 1989 TO 2015

EHA Library, Avinash Dinmohamed, 215601

NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AS A BIOMARKER IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: DATA FROM A PHASE II TRIAL OF POMALIDOMIDE PLUS DEXAMETHASONE

EHA Library, Katja Weisel, 215602

REAL WORLD CLINICAL IMPLICATIONS OF THE LIMITATIONS ASSOCIATED WITH THE REVISED INTERNATIONAL STAGING SYSTEM: UNSELECTED PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NOVEL AGENTS IN AGEING SOCIETY

EHA Library, Yoshiaki Abe, 215603

EVALUATION OF MINIMAL RESIDUAL DISEASE USING NEXT GENERATION FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS

EHA Library, Ioannis Kostopoulos, 215604

EARLY LIGHT CHAIN KINETICS AND DEPTH/DURATION OF HEMATOLOGIC RESPONSES TO DARATUMUMAB IN PREVIOUSLY TREATED LIGHT CHAIN AMYLOIDOSIS

EHA Library, Gregory Kaufman, 215605

EFFICACY AND TOLERABILITY OF DARATUMUMAB AFTER ALLOGENEIC TRANSPLANTATION FOR HEAVILY TREATED MULTIPLE MYELOMA.

EHA Library, ANA PILAR GONZALEZ RODRIGUEZ, 215606

CHARACTERISTICS, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN NORTH AMERICA AND EUROPE: FINDINGS FROM THE PREAMBLE STUDY

EHA Library, Ravi Vij, 215607

COMPLETE RESPONSE AND INDUCTION TREATMENT DOES NOT AFFECT SURVIVAL IN MYELOMA PATIENTS RELAPSING WITHIN 18 MONTHS FOLLOWING UP-FRONT HDM-ASCT. A POPULATION-BASED STUDY FROM 1994 TO 2015

EHA Library, Annette Vangsted, 215608

OVERALL SURVIVAL OF PATIENTS POST-TRANSPLANT: STUDY RESULTS FROM TWO PHASE 3 TRIALS ASPIRE AND ENDEAVOR

EHA Library, Hartmut Goldschmidt, 215609

DURABLE PROGRESSION-FREE SURVIVAL BENEFIT IN EARLY RESPONDERS TO ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF 4-YEAR DATA FROM ELOQUENT-2

EHA Library, Christof Scheid, 215610

SERIAL SERUM FREE LIGHT CHAIN ASSAY CAN REDUCE THE NEED FOR 24-HOUR URINE PROTEIN ASSESSMENT FOR RESPONSE ASSESSMENT IN MULTIPLE MYELOMA

EHA Library, Marcella Tschautscher, 215611

NOVEL THERAPIES DIFFERENTIALLY IMPACT POLYCLONAL IMMUNOGLOBULIN RECOVERY IN MYELOMA PATIENTS: A LONGITUDINAL STUDY

EHA Library, Mauricette Michallet, 215612

REAL-WORLD OUTCOMES IN TRANSPLANT INELIGIBLE NDMM PATIENTS: RESULTS FROM A LARGE UK COHORT

EHA Library, Faouzi Djebbari, 215613

BONE MARROW PLASMA CELL INFILTRATION IN LIGHT-CHAIN AMYLOIDOSIS: IMPACT ON ORGAN INVOLVEMENT AND OUTCOME

EHA Library, Luis Gerardo Rodríguez-Lobato, 215614

TREATMENT OF IGM-ASSOCIATED SYSTEMIC AL AMYLOIDOSIS WITH RITUXIMAB-BENDAMUSTINE

EHA Library, Richa Manwani, 215615

TANDEM TRANSPLANTATION OVERCOMES POOR PROGNOSIS IN NEWLY DIAGNOSED EXTRAMEDULLARY MYELOMA WITH HIGH-RISK CYTOGENETICS: A RETROSPECTIVE STUDY BY THE CMWP-EBMT

EHA Library, Nico Gagelmann, 215616

VENETOCLAX MONOTHERAPY AND COMBINED WITH DEXAMETHASONE AS TARGETED THERAPY FOR RELAPSED/REFRACTORY T(11;14) MULTIPLE MYELOMA

EHA Library, Jonathan L Kaufman, 215617

SUBCUTANEOUS DARATUMUMAB (DARA SC) + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: SAFETY RUN-IN RESULTS OF ANDROMEDA

EHA Library, GIAMPAOLO MERLINI, 215618

DISEASE ASSESSMENT BY PET-CT PLUS FLOW CYTOMETRY IN MULTIPLE MYELOMA IDENTIFIES PATIENTS WITH DIFFERENT SURVIVAL OUTCOMES

EHA Library, RAFAEL ALONSO FERNÁNDEZ, 215619

PREDICTORS OF HEMATOLOGIC AND ORGAN RESPONSE IN AL AMYLOIDOSIS

EHA Library, Giovanni Palladini, 215620

IXAZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE FOR INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Heinz Ludwig, 215621

SELINEXOR COMBINED WITH LOW DOSE BORTEZOMIB AND DEXAMETHASONE (SVD) INDUCES A HIGH RESPONSE RATE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM)

EHA Library, Nizar Bahlis, 215622

THE MAJORITY OF NEWLY DIAGNOSED MYELOMA PATIENTS DO NOT FULFIL THE INCLUSION CRITERIA IN CLINICAL PHASE III TRIALS

EHA Library, Tobias Klausen, 215623